Emergent Biosolutions Cash on Hand 2010-2022 | EBS

Emergent Biosolutions cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Emergent Biosolutions Annual Cash on Hand
(Millions of US $)
2021 $576
2020 $622
2019 $168
2018 $112
2017 $179
2016 $272
2015 $308
2014 $280
2013 $179
2012 $142
2011 $146
2010 $171
2009 $103
Emergent Biosolutions Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $436
2021-12-31 $576
2021-09-30 $404
2021-06-30 $448
2021-03-31 $548
2020-12-31 $622
2020-09-30 $415
2020-06-30 $269
2020-03-31 $182
2019-12-31 $168
2019-09-30 $139
2019-06-30 $178
2019-03-31 $137
2018-12-31 $112
2018-09-30 $340
2018-06-30 $191
2018-03-31 $165
2017-12-31 $179
2017-09-30 $342
2017-06-30 $316
2017-03-31 $270
2016-12-31 $272
2016-09-30 $299
2016-06-30 $333
2016-03-31 $341
2015-12-31 $308
2015-09-30 $309
2015-06-30 $215
2015-03-31 $217
2014-12-31 $280
2014-09-30 $242
2014-06-30 $168
2014-03-31 $160
2013-12-31 $179
2013-09-30 $173
2013-06-30 $156
2013-03-31 $130
2012-12-31 $142
2012-09-30 $198
2012-06-30 $162
2012-03-31 $150
2011-12-31 $146
2011-09-30 $129
2011-06-30 $127
2011-03-31 $143
2010-12-31 $171
2010-09-30 $151
2010-06-30 $102
2010-03-31 $117
2009-12-31 $103
2009-09-30 $119
2009-06-30 $103
2009-03-31 $61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.599B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00